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ORIGINAL ARTICLE
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ABSTRACT
Objectives: Resistance-associated substitutions (RASs) may impair treatment response to direct-acting
antivirals (DAA) in hepatitis C virus (HCV) treatment. We investigated the effects of baseline NS3-RASs
(Q80K and R155K) and clinically relevant NS5A-RASs in patients with HCV genotype (GT) 1a infection
on treatment outcome, with or without resistance-based DAA-treatment. This multi-center study was
carried out between 2014 and 2016.
Patients/methods: Treatment in the intervention group (n¼ 92) was tailored to baseline resistance.
Detection of NS3-RAS led to an NS5A-inhibitor-based regimen and detection of NS5A-RAS to a prote-
ase-inhibitor regimen. Patients without baseline RAS in the intervention group and all patients in the
control group (n¼ 101) received recommended standard DAA-treatment.
Results: The sustained virologic response rates (SVR) in the intervention and control groups were
97.8% (90/92) and 93.1% (94/101), respectively (p¼ .174). A trend toward higher SVR-rate in cirrhotic
patients (p¼ .058) was noticed in the intervention group compared to the control group with SVR-
rates 97.5% (39/40) and 83.3% (35/42), respectively. All patients with baseline NS3 (Q80K/R155K) or
NS5A-RASs in the intervention group achieved SVR with personalized resistance-based treatment. In
the control group, five patients with Q80K or R155K at baseline were treated with simepre-
virþ sofosbuvir and treatment failed in two of them. Furthermore, one of three patients who failed
ledipasvirþ sofosbuvir treatment had NS5A-RASs at baseline.
Conclusions: In line with the findings of the OPTIMIST-2 trial for Q80K and the EASL-guidelines 2016
for NS5A-RASs, baseline RASs appeared to have an impact on treatment outcome albeit a statistical
significance was not observed in this low-prevalence population.
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Hepatitis C virus (HCV) infection is a major cause of chronic
liver disease, liver cirrhosis, hepatocellular carcinoma (HCC)
and liver failure [1]. Globally, the prevalence of viremic HCV
infection is estimated to be around 1.1%, corresponding to
64–103 million actively infected individuals [2]. In Sweden and
Norway, about 0.4–0.5% of the population is infected with
HCV, i.e., approximately 45,000 and 20,000 individuals, respect-
ively [3–5]. HCV is classified into seven genotypes (GT) and
several subtypes [6]. In Sweden, the most common GT is 1a,
followed by 3a [7], while in Norway GT 3a is the most com-
mon, followed by 1a (personal communication Gutteberg T).
The development of direct-acting antiviral agents (DAAs) has
led to major advances in the treatment of HCV infection, with
substantially higher sustained virologic response (SVR) rates,
shorter treatment duration and fewer side effects than previous
interferon-based treatment. Currently, four classes of DAAs are
available targeting three nonstructural proteins in HCV; NS3/4A
protease inhibitors (PI), NS5A inhibitors and nucleoside and non-
nucleoside inhibitors of the NS5B RNA-dependent RNA
CONTACT Johan Lennerstrand johan.lennerstrand@medsci.uu.se Department of Medical Sciences, Section of Clinical Microbiology, Uppsala University,
Hubben, plan 5, Dag Hammarskj€old v€ag 38, SE-752 37 Uppsala, Sweden.
Supplemental data for this article can be accessed here.
 2018 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.
This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License ((http://creativecommons.org/licenses/by-nc-nd/4.0/),
which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way.
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY
2018, VOL. 53, NO. 10-11, 1347–1353
https://doi.org/10.1080/00365521.2018.1511824
polymerase (RdRP) [8]. Treatment with different combinations of
these potent DAAs with or without ribavirin has made it
possible to obtain SVR rates of above 95% in the majority of
patients with chronic hepatitis C (CHC).
HCV displays a pronounced genetic heterogeneity due to
the lack of proofreading activity of the RdRP and the rapid
turnover rate in HCV replication [9]. In the resulting HCV qua-
sispecies, resistance-associated substitutions (RASs) can
emerge under the selective pressure of treatment with DAAs
[10], but may also occur prior to treatment, i.e., baseline resist-
ance [9]. Depending on their frequency within the HCV qua-
sispecies and the level of resistance conferred, baseline RAS
can contribute to treatment failure in the presence of other
negative predictive factors such as advanced stages of liver
fibrosis, previous treatment and suboptimal treatment [8].
These methods available for detecting RASs are the
Sanger sequencing and the next-generation sequencing
(NGS) methods. The Sanger sequencing method carries a
20% cutoff level for detecting RASs in the viral population
compared to 1% with the NGS method. However, the gen-
eral consensus is to recommend a cutoff level of 10–20%, for
detecting RASs within the HCV quasispecies, in order to be
of clinical relevance in predicting treatment failures [11].
The polymorphism Q80K, a naturally occurring amino acid
substitution in the viral NS3 region, is mainly present in HCV
GT 1a and is associated with reduced susceptibility to the
NS3/4A protease inhibitor simeprevir, as indicated by the
COSMOS and the first OPTIMIST studies [12,13]. The preva-
lence of baseline Q80K varies geographically and is reported
to be 48% in the USA [14], compared to 5.7–15.2% in
Sweden [7,15], and 4.8% in Norway [15].
The NS3 amino acid substitution R155K confers resistance
to PI and is frequently observed in GT 1a-infected patients
who failed to achieve SVR after treatment with boceprevir,
telaprevir or simeprevir [10]. R155K can also be present in
<1% of GT 1a PI treatment-naïve patients [16].
In current clinical practice, it is more important to con-
sider baseline RASs in NS5A than NS3 for GT 1a. Many RASs
confer a very high fold resistance, e.g., Y93H/N (>1000 fold),
with GT 1a in in vitro replicon assays [8]. It should be noted
that NS5A RASs at positions 30 and 31 confer a medium to
high resistance, but these in vitro resistance profile might
not be high enough to be of clinical importance for current
approved NS5A inhibitors (with exception of elbasvir and
ledipasvir). Nevertheless, these NS5A RASs are rarely found
as baseline polymorphisms in GT 1a patients, i.e., in 2–5% of
DAA treatment-naïve patients when using the population-
sequencing method. However, EASL and AASLD guidelines
recently recommended NS5A baseline testing for GT 1a prior
to treatment with elbasvir and that testing should also be
considered in treatment-experienced patients before treat-
ment with ledipasvir regimens [17,18].
At the start of the study, there were no available guide-
lines regarding baseline resistance testing. The aim of this
real-life study was initially to investigate the impact of Q80K,
subsequently also including R155K and NS5A RASs, on treat-
ment outcome in GT 1a infected patients treated with DAAs,
and to evaluate the resultant economic consequences.
Known factors influencing treatment outcome were eval-
uated. The study was conducted during 2014–2016 when
simeprevir plus sofosbuvir combination was a recommended
alternative to NS5A inhibitor based regimes.
Patients and methods
Patients diagnosed with chronic HCV GT 1a infection from
Uppsala, G€avle and Tromsø received resistance-based treat-
ment (intervention group) and from €Orebro, Falun and Bod€o
received treatment according to the national guidelines
[19,20] without previous resistance testing (control group).
They were consecutively included in this real-life, open-label,
non-randomized Nordic multi-center study from 1 April 2014
to 30 June 2015 (Sweden) and 26 January 2016 (Norway).
During this period, baseline NS3 resistance testing (Q80K and
R155K) of HCV GT 1a was performed routinely for the inter-
vention group. In January 2015, when the fixed combination
ledipasvir plus sofosbuvir was approved in Sweden and
Norway, analysis of NS5A RAS was introduced and was per-
formed in the intervention group, approximately 40% of 92
patients in the intervention group. The NS5A RASs consid-
ered important by us at that time were Q30E/H/R, L31M and
Y93C/H/N. All these RASs were indicated by the HCV drug
development advisory group to be clinically relevant with
a> 100 fold increase in resistance toward ledipasvir [10].
Recommended treatment, according to the National
Boards [19,20], was, therefore, given to patients without
baseline RASs in the intervention group and to all patients in
the control group. For patients in the intervention group
with Q80K or R155K mutation, the treatment was amended
to a NS5A inhibitor-based regimen. In case of baseline NS5A
RAS, treatment with a protease inhibitor-based regimen i.e.,
simeprevir plus sofosbuvir was considered. Presence of base-
line NS3 RASs were analyzed for all patients in the control
group retrospectively, whereas baseline NS5A analysis in the
control group was only done (also retrospectively) for those
that had failed ledipasvir plus sofosbuvir treatment.
Resistance analyses for emerging RASs were performed in
all non-responders at the time of relapse; NS3A analysis in
simeprevir failures and NS5A analysis in patients with failure
after the treatment with NS5A inhibitor-based regimen.
Ribavirin was added at the responsible medical doctors
(MD) discretion, mainly due to the presence of cirrhosis.
The inclusion criteria were: infection with HCV GT 1a; 18
years of age; informed consent; and treatment according to
Swedish and Norwegian consensus recommendations as well as
completed treatment course (per-protocol). Patients included
were either treatment-naive or treatment-experienced to inter-
feron-based therapy, including triple therapy containing the first
generation NS3 protease-inhibitors boceprevir or telaprevir.
Patients previously treated with other DAAs were excluded.
Liver elasticity (kPa) was measured with FibroScanVR 502
(Echosens, Paris, France) (Swedish study sites) and
FibroScanVR 402 (Norwegian study sites) by experienced
nurses or doctors. For patients who had undergone a liver
biopsy, the Metavir score was recorded [21]. Presence of cir-
rhosis was determined by FibroScan >12.5 kPa or Metavir
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score 4 in liver biopsy. Child-Pugh score was estimated from
available information on the level of liver elasticity [22], bio-
chemical results and ultrasound. Patient data were extracted
from the medical records by the responsible MD at each
study site, anonymized and transferred to a joint database.
SVR was defined as undetectable HCV RNA 12 weeks after
the end of treatment. Non-SVR was regarded as a viral break-
through (a negative viral load nadir followed by a positive
HCV RNA level during therapy), or viral relapse (non-detect-
able viral load at the end of treatment followed by an
increase in HCV RNA level after therapy).
Laboratory methods
The Clinical Microbiology laboratory at the University
Hospital, Uppsala, performed the resistance analysis of RASs
(baseline and emerging). A nested PCR method, followed by
Sanger sequencing (population sequencing, cutoff 20%)
method was adopted for the NS3 resistance analysis. The
pan-genotypic NS3 resistance method has been described
elsewhere [7]. In brief, RNA extraction from the samples was
done using the BioMerieux NucliSENSVR easyMAGTM system
(bioMerieux, Marcy-l’Etoile, France). cDNA was synthesized
from RNA template with the SuperScriptTM III Reverse
Transcriptase (InvitrogenTM, Thermo Fisher, Waltham, MA,
USA) using random hexamers. First round PCR and nested
PCR were performed with in-house primers targeting parts of
the NS3 region using the Taq PCR Master Mix (Qiagen,
Hilden, Germany). The integrity of the nested PCR products
was verified by agarose-gel electrophoresis. PCR-positive
samples were purified using QIAquickVR PCR Purification Kit
(QIAgen, Hilden, Germany). All protocols used were per-
formed according to the manufacturer’s instructions. The
purified products were sequenced by the Sanger sequencing
method using the same primers used in the nested PCR. The
HCV NS3 sequences were analyzed using SeqScapeVR
Software version 2.6 (Applied Biosystems, Foster City, CA).
The NS3 sequence of GT 1a H77 strain was used as a refer-
ence template. The mutations were interpreted as relevant
NS3 RASs by comparing with RASs reported in the literature
[10,23]. The NS5A resistance analysis was performed with the
same method and is described elsewhere [24].
HCV RNA titer quantification was performed at the
Department of Clinical Microbiology, University Hospital,
Uppsala, Sweden and at the Department of Microbiology
and Infection Control, University Hospital of North Norway,
Tromsø, Norway using Roche COBASVR AmpliPrep/TaqManVR
HCV Quantitative Test version 2.0 with a LOQ of 15 IU/mL
(Roche Molecular Systems Inc., Branchburg, NJ).
Outcomes
The primary objective was to study the treatment efficacy in
the intervention group compared to the control group, with
respect to the proportion of patients achieving SVR.
Secondary objectives included to determine (1) the propor-
tion of patients with baseline NS3 (Q80K and R155K) RASs,
(2) the proportion of patients with baseline NS3 and NS5A
RASs experiencing viral breakthrough or relapse, (3) the pro-
portion of patients with baseline NS3 RASs not experiencing
viral breakthrough or relapse and (4) to compare total
expenditures (treatment and baseline analysis costs) per cap-
ita in the two study groups.
Statistics
The null hypothesis of this study was that the SVR rate is equal
in the intervention and control groups. The basic statistical
computing was done in MicrosoftVR ExcelVR 2013 (Microsoft
Office professional plus 2013, Microsoft Corporation) and in
Statistical Package for Societal Sciences (SPSS version 24, SPSS
Inc., Chicago, IL). The Fishers exact test was used to test the dif-
ferences between groups (small expected cell count). A two-
tailed p value <.05 was considered significant.
Ethics
The regional committee of medical research ethics
Committee in Uppsala (Dnr: 2013/185 and Dnr: 2013/185/1)
and the Data Protection Official at The University Hospital of
Northern Norway (Nr. 0574) approved the study. All partici-
pants received written information and the opportunity to
withdraw from the study.
Results
Patient baseline characteristics
In total, 200 patients were assessed to be eligible for the
study. Samples from 196 patients were available for baseline
resistance analyses (95 in the intervention group and 101
analyzed retrospectively in the control group). In the inter-
vention group, three patients were omitted from further
analyses; two of them died before the time of evaluation
for SVR and one patient started treatment before the result
of the baseline resistance analysis was available. Thus, week
12 follow-up data were obtained from 193 patients; 92 in
the intervention group and 101 in the control group
(Figure 1).
Demographic and baseline clinical characteristics are
provided in Table 1. The majority of patients were treat-
ment-naïve and male. The median age was 56 years. The
distribution of patients with cirrhosis and baseline NS3
RASs (Q80K and R155K) in the intervention and the control
groups were similar. The majority of cirrhotic patients were
Child-Pugh A.
Table 2 shows treatment characteristics. The proportion of
patients treated with simeprevir was higher in the interven-
tion group compared to the control group. Most of the
patients received treatment for 12 weeks and ribavirin was
added to a minority.
Efficacy and baseline RASs
The overall prevalence of baseline Q80K and R155K polymor-
phisms was 7.1% (14/196) and 5.2% (10/196), respectively.
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The prevalence of Q80K in Sweden and Norway was 7.0%
(11/158) and 10.5% (4/38), respectively. The prevalence of
R155K in Sweden and Norway was 4.4% (7/158) and 7.9% (3/
38), respectively. Prevalence data of NS5A RASs could not be
specified since the mandatory screening of baseline NS5A
RASs was not started until January 2015, and done only for a
part of the intervention group. However, three patients with
baseline NS5A RASs were found: two in the intervention
group (M28T and Y93H), and one in the control group that
harbored both M28A and Q30R.
The SVR rate in the intervention group and the control
group was 97.8% (90/92) and 93.1% (94/101), respectively
(p¼ .174). A trend toward higher SVR rates in cirrhotic
patients (p¼ .058) was noticed in the intervention group
compared to the control group, 97.5% (39/40) and 83.3%
(35/42), respectively (Figure 2). Overall, liver cirrhosis was
associated with a lower SVR12 rate compared to non-cirrho-
sis, 90 (74/82) and 99% (110/111), respectively (p¼ .005).
NS3 RASs
In the intervention group, all patients with baseline Q80K
(n¼ 5) and R155K (n¼ 6) were successfully treated with a
regimen containing a NS5A inhibitor. In the control group,
the SVR rates in patients with baseline Q80K and R155K were
89% (8/9) and 75% (3/4), respectively. Only five of 13
patients with such RASs at baseline were treated with sime-
previr plus sofosbuvir in the control group. Notable, of this
one in four (1/4) patients with Q80K RAS and one in one
(1/1) with R155K RAS failed treatment (Figure 2).
Table 1. Patient demographics and baseline characteristics.
Intervention group (N¼ 92 ) Control group (N¼ 101) p
Median age, year (range) 56 (27–74) 56 (28–74) .9
Sex, male, n (%) 61 (66) 70 (69) .8
Cirrhosis, n (%) 40 (43) 42 (42) .9
Child A, n (%) 35 (87.5) 40 (95.2) –
Child B, n (%) 5 (12.5) 2 (4.8) –
Child C, n (%) 0 0 –
Median HCV RNA, log10 IU/ml (range) 6.1 (3.3–7.5) 6.1 (4.4–7.2) .7
Baseline Q80K and R155K RAS, n (%) 11 (12.0%) 13 (12.9) .6
HCV antiviral treatment history, n (%) .07
Treatment-naïve 45 (48.9) 67 (66.3) –
Non-responder 21 (22.8) 14 (13.9) –
Relapse/ breakthrough 19 (20.7) 12 (11.9) –
Othera 7 (7.6) 8 (7.9) –
Previous therapy with PIb, n (%) 11 (12.0) 6 (5.9) .2
aReinfection, discontinuation.
bPI: protease inhibitor (boceprevir or telaprevir).
Figure 1. Flowchart of patients included in the study. Baseline resistance testing in the control group was performed retrospectively.
Table 2. Treatment characteristics.
Intervention
group (N¼ 92 )
Control
group (N¼ 101) p
Treatment regime, n (%) .023
Simeprevirþ Sofosbuvir 46 (50.0) 30 (29.7) –
Ledipasvirþ Sofosbuvir 34 (37.0) 58 (57.4) –
Daclatasvirþ Sofosbuvir 11 (12.0) 11 (10.9) –
OBV/PTV/rþDSVa 1 (1.0) 2 (2.0) –
Addition of ribavirin, n (%) 14 (15.0) 9 (8.9) .2
Treatment duration, week (%) .4
8 5 (5.4) 3 (3.0) –
12 73 (79.3)b 88 (87.1) –
16 3 (3.3) 1 (1.0) –
24 11 (12.0) 9 (8.9) –
aOmbitasvir/paritaprevir/ritonavirþ dasabuvir.
bOne patient scheduled for 12 weeks of treatment discontinued after 4 weeks
because of an accident, but achieved SVR.
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NS5A RASs
In the intervention group, all patients with baseline
NS5A RASs (n¼ 2) were successfully treated. The patient
with Y93H was treated with simeprevir plus sofosbuvir,
whereas the patient with M28T was treated with ledi-
pasvir plus sofosbuvir since the M28T was not consid-
ered a clinically relevant NS5A RAS. In the control
group, three patients failed ledipasvir plus sofosbuvir
treatment and one of these patients harbored a relevant
NS5A RAS at baseline Q30R (together with M28A)
(Supplementary Table S1).
In total, nine patients failed to achieve SVR, the reason for
non-SVR was a viral relapse. In three of these nine patients,
Q80K, R155K and Q30R one each, were detected at baseline
(all in control group). Majority of the 10 observed baseline
R155K was connected with prior boceprevir or telaprevir
treatment failure, but in one patient, it was found as a nat-
ural polymorphism. Overall, patients with treatment failure
were all male, had a median age of 56 years, 89% (8/9) of
them had liver cirrhosis and most were treatment naïve (6/9)
(Table 3).
Supplementary Table S1 gives an overview of the patients
with detected baseline NS3 RASs (Q80K and R155K) and
NS5A RASs.
Economic implications
In 2014/2015, the cost of simeprevir plus sofosbuvir treatment
for 12 weeks was 750,000 NOK/650,000 SEK. In 2015, the price
for 12 weeks of ledipasvir plus sofosbuvir treatment was
500,000 NOK/400,000 SEK. Baseline NS3 RAS was detected
retrospectively in two patients who experienced virological
relapse after treatment with simeprevir plus sofosbuvir.
Switching these two patients to a NS5A inhibitor-based regi-
men could possibly have reduced treatment costs and in add-
ition, contributed to a best practice approach. The same trend
occurred with the use of simeprevir plus sofosbuvir treatment
for the patient with NS5A Q30R RAS at baseline. Thus, in the
control group, there was an economic loss of 2.0 million NOK/
1.7 million SEK compared to the intervention group where no
patients with Q80K/R155K or clinically important NS5A RAS at
baseline experienced non-SVR. In comparison, the baseline
analysis costs (2000 NOK/SEK per analysis) for the 95 patients
in the intervention group were less than 0.2 million NOK/SEK.
Discussion
In this real-life study conducted in Q2 2014 to Q1 2016, we
found a low prevalence of baseline Q80K RAS in HCV GT 1a
Figure 2. Sustained virologic response rates (SVR) in the intervention and control groups. SVR rates in the intervention group (dark grey bars) and the control
group (light grey bars). The two bars to the right show SVR rates by simeprevir treatment in patients with baseline Q80K and R155K RAS in the control group.





















60 I 4 (B) 42.8 Sþ S N 5.2 0 R155K Yes 12
54 I 3 10.4 Sþ S NR 5.7 0 0 No 12
56 C 4 (A) – Sþ S N 6.1 0 0 Yes 12
46 C 4 (A) – Sþ S N 6.2 R155K R155K No 12
66 C 4 (A) – Lþ S N 6.9 0 Q30Rþ L31M No 12
59 C 4 (A) – Lþ S NR 6.0 0 L31I No 12
52 C 4 (A) 75 Sþ S NR 5.8 0 D168A No 12
52 C 4 (B) 75 Sþ S N 4.8 Q80K Q80K No 12
65 C 4 (A) 47.2 Lþ S N 6.4 M28A, Q30R M28A, Q30R Yes 12
I: intervention group; C: control group; Lþ S: ledipasvir plus sofosbuvir; N: naïve; NR: null responder to pegylated interferon plus ribavirin; Sþ S: simeprevir
plus sofosbuvir
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in Sweden and Norway (7.1%), which is in line with previous
studies [7,15]. Liver cirrhosis was significantly associated with
treatment failure. There were not enough GT 1a patients
with Q80K RAS to detect a significant effect of baseline
resistance-guided treatment on the SVR rate. However, our
findings appear to agree with earlier studies. The COSMOS
study in 2014 indicated lower SVR rates in GT 1a patients
with baseline Q80K RAS compared to patients without Q80K
at baseline [13]. The OPTIMIST-2 study revealed lower SVR
rates for GT 1a patients with cirrhosis and baseline Q80K
(SVR 74%) compared to those without Q80K (SVR 92%) [25].
In the control group, only 30% of the patients were
treated with simeprevirþ sofosbuvir combination compared
to 50% in the intervention group, possibly due to new treat-
ment guidelines introduced in February (Sweden) and March
(Norway) 2015, which recommended treatment with the
fixed combination of ledipasvir plus sofosbuvir. Thus, these
guidelines recommended NS5A inhibitor-based regimens for
previous treatment failures of boceprevir/telaprevir, without
regard to baseline resistance analysis. Of note, the only
patient in the control group with Q80K at baseline that failed
treatment was one out of four patients with such RAS that
were treated with simeprevir plus sofosbuvir (i.e., SVR 75%).
Furthermore, the single patient with baseline R155K that
underwent simeprevir plus sofosbuvir treatment in the con-
trol group also failed to attain SVR.
Our study also indicated that baseline resistance analysis
may have an impact on treatment outcome in patients with
liver cirrhosis, but the difference was not statistically signifi-
cant, possibly due to the low prevalence of baseline NS3 and
NS5A RASs.
Currently, the NS3 inhibitor simeprevir is no longer in use
due to the development of more effective DAA treatment
regimens. As a result, the focus has switched to study base-
line NS5A RASs in predicting the most effective DAA combin-
ation and treatment duration [11]. Since 2016, NS5A baseline
resistance analysis is mainly recommended before treatment
of GT 1a with the NS5A inhibitor elbasvir, co-formulated with
the NS3 inhibitor grazoprevir. However, it is also recom-
mended to consider baseline analysis of the NS5A RASs for
treatment-experienced GT 1a patients prior to treatment
with ledipasvir plus sofosbuvir [17,18]. Therefore, it was rele-
vant for this study, when conducted in 2015, to include also
baseline NS5A analysis.
Although we cannot report any significant effect on base-
line Q80K/R155K and NS5A resistance analyses on the treat-
ment outcome, baseline resistance testing could have
economic implications. However, today’s considerably lower
drug expenditures per patient combined with recommended
regimens that are less dependent on the preexisting RASs
addressed in this study, made our economic calculations
somewhat obsolete.
In clinical practice, the impact of HCV RASs will probably
become less important with the availability of new effective
DAAs. However, drug resistance can be a problem in the
context of other negative predictors for treatment response
like the presence of cirrhosis, suboptimal treatment duration
and prior treatment [8,11], and new emerging mutations in
the highly variable HCV genome may affect the current high
SVR rates. It could be noted that the Q80K RAS was the
most commonly observed baseline NS3 variant in the few
failures in the POLARIS-2 trial [26]. In patients with GT 1a
treated with the pan-genotypic NS3 protease inhibitor voxi-
laprevir combined with sofosbuvir plus velpatasvir for eight
weeks, the SVR rate was lower in patients with baseline
Q80K compared to patients without (88 and 94%, respect-
ively) [26].
Conclusion
We found a low prevalence of NS3 Q80K RAS in HCV GT 1a
in Norway and Sweden. In this real-life study, baseline resist-
ance analyses for NS3 RAS (Q80K and R155K) and clinically
relevant NS5A RASs could not statistically determine the
treatment outcome, probably due to small sample sizes.
Liver cirrhosis was the most important predictor of treatment
failure. However, the results indicate an adverse effect of RAS
Q80K preexistence on the treatment outcome with simepre-
vir plus sofosbuvir, findings that were published in the
OPTIMIST-2 trial in 2016. Furthermore, the results are in line
with the recommendations by EASL in 2016 that NS5A RASs
at baseline appeared to have an impact on ledipasvir plus
sofosbuvir treatment outcome. Personalized treatment with
regard to baseline resistance analyses could thereby be
important to find the most cost-effective treatment combina-
tions/duration, both in a perspective of evidence-based
healthcare delivery and in the case of the individual patient
to avoid relapse and reducing the retreatment options.
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